Table 2.

Assessment of efficacy in patients received radical resection

Time from the end of radiotherapy to surgery [median (range)] days	61 (43–84)
R0 resection (yes/no)	46 (100.0%) / 0 (0.0%)
Anal-preserving (yes/no)	41 (89.1%) / 5 (10.9%)
Defunctioning ileostomy	13 (28.3%)
Colostomy	5 (10.9%)
No stomas	28 (60.9%)
AJCC tumor regression grade (0/1/2/3)	20 (43.5%) / 15 (32.6%) / 9 (19.6%) / 2 (4.3%)
ypT category (ypT0/ypT1/ypT2/ypT3/ypT4)	21 (45.7%) / 4 (8.7%) / 4 (8.7%) / 16 (34.8%) / 1 (2.2%)
ypN category (ypN0/ypN1/ypN2)	41 (89.1%) / 4 (8.7%) / 1 (2.2%)
MRI tumor regression grade (0/1/2/3)	18 (39.1%) / 22 (47.8%) / 5 (10.9) / 1 (2.2%)
ycT category (ycT0/ycT1/ycT2/ycT3/ycT4)	18 (39.1%) / 5 (10.9) / 7 (15.2%) / 14 (30.4%) / 2 (4.3%)
ycN category (ycN0/ycN1/ycN2)	40 (87.0%) / 4 (8.7%) / 2 (4.3%)
Clinical evaluation through RECIST
CR	18 (39.1%)
PR	18 (39.1%)
SD	10 (21.7%)
PD	0 (0%)
ORR	35 (76.1%)
Neoadjuvant rectal score [median (range)]	14.98 (0.94–70.34)

AJCC American Joint Committee on Cancer, MRI magnetic resonance imaging, RECIST Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate